Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation ( compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Significant disability assessed using Liverpool Outcome Score RR (M‐H, random‐effects analysis, 95% CI) · children with acute encephalitis
It is very uncertain whether intravenous immunoglobulin with or without standard care changes significant disability assessed using Liverpool Outcome Score RR… compared with standard care alone or placebo (very low certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · children with acute encephalitis
It is very uncertain whether intravenous immunoglobulin with or without standard care changes ≥ 1 serious adverse event RR (M‐H, random‐effects analysis, 95% CI) compared with standard care alone or placebo (very low certainty).
1 finding from 1 review
Length of hospital stay · children with acute encephalitis
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
3 studies · 172 participants
Low
no estimate extracted
3 studies · 162 participants
Low
no estimate extracted
5 studies · 257 participants
Low
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response at 3 months · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
1 finding from 1 review
Relapse at 3 months · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious infection · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose
Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review